Navigation Links
ChromaDex® Names Debra Heim as COO
Date:2/21/2012

IRVINE, Calif., Feb. 21, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries and marketer of BluScience™ (http://www.bluscience.com), its recently launched line of dietary supplements, announced today the Board has appointed Debra A. Heim as the company's Chief Operating Officer and President of its Consumer Products Division.

(Logo:  http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

Debra Heim, age 43, has over 20 years of experience with consumer brands companies. Prior to joining ChromaDex, Ms. Heim spent 16 years with The Himmel Group (www.himmelgroup.com) where she served as its President and Chief Operating Officer since 2010. Previously, she served as the company's Chief Financial Officer for 12 years. During her tenure with The Himmel Group, Ms. Heim was part of the executive management team overseeing sales and marketing of the GOLD BOND MEDICATED POWDER and OVALTINE® businesses. Additionally, Debra built and managed the organization responsible for the manufacturing, sales order processing, distribution, accounting and finance, information technology systems, human resources and consumer services of the company.

Commenting on the announcement, ChromaDex's CEO Jeffrey Himmel stated, "Having personally worked with Debra for more than 15 years, I am thrilled to have her join the executive management team at ChromaDex. Her experience and skill sets with branded consumer products are an ideal fit, as we are just beginning the national retail launch of our BluScience line of dietary supplements."

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® (http://www.pteropure.com) pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its BluScience™ line of dietary supplements. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

ChromaDex Investor Contact:                                             
Liviakis Financial Communications, Inc.                         
John M. Liviakis, President                                                       
415-389-4670
John@Liviakis.com

Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

ChromaDex/BluScience Contact:
Jeffrey Himmel, CEO
949-419-0288
jsh@chromadex.com


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson
2. ChromaDex® Announces Management Changes
3. Entomological Society of America names 2008 award winners
4. American Library Association names NJIT prof’s Whale Music book a top ten
5. WCC Smart Search and Match Names Rudie Lion - Product Marketing Manager
6. WCC Smart Search and Match Names Rudie Lion - Product Marketing Manager
7. WCC Smart Search & Match Names Tarvinder Sembhi as VP Sales for the ID Market
8. Names turn preschoolers into vegetable lovers
9. AIBS names 2009 emerging public policy leaders
10. UC Riverside researcher names lichen after President Barack Obama
11. Impact Factor names Cell top research journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by ... Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region - ... grow from USD 10.74 Billion in 2015 to reach USD 32.73 Billion ... Continue Reading ... ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... CLEVELAND , Nov. 30, 2016  GenomOncology today announced ... Vice President of Medical Affairs.  Dr. Coleman ... enhancing the company,s proprietary knowledge-enabled platform. The GenomOncology software suite ... of genetic sequencing data and clinical decision support, from quality ... , ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
(Date:11/30/2016)... 2016   Merck , ein führendes ... einer Reihe von Vereinbarungen mit Evotec AG ... Screeningleistungen für Mercks Palette genetischer Reagenzien wie ... diese Bibliotheken in Kombination mit Evotecs Expertise ... zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
(Date:11/30/2016)... ... November 30, 2016 , ... Energetiq Technology, a world leader ... generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at the MRS Fall Exhibit 2016. ... offers higher radiance and irradiance from a truly broadband white light source. The ...
Breaking Biology Technology: